BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
BeiGene (NASDAQ: BGNE) has opened its flagship U.S. facility in Hopewell, N.J., representing an $800 million investment in biologics manufacturing and clinical R&D capabilities. The 42-acre site features 400,000 square feet of commercial-stage biologic pharmaceutical manufacturing capacity, with room for expansion. This facility enhances BeiGene's ability to produce innovative cancer medicines at scale, reduce costs, and ensure supply chain resiliency.
The company plans to create hundreds of skilled high-tech jobs by the end of 2025. The site includes sustainability measures such as a heating and cooling system using recycled wastewater and is solar-ready. This expansion supports BeiGene's global growth strategy and strengthens its position as a leading oncology innovator with over 30 molecules at clinical or commercial stage.
BeiGene (NASDAQ: BGNE) ha aperto il suo stabilimento principale negli Stati Uniti a Hopewell, N.J., rappresentando un investimento di 800 milioni di dollari nella produzione di biologici e nelle capacità di ricerca e sviluppo clinico. Il sito di 42 acri dispone di 400.000 piedi quadrati di capacità di produzione farmacologica biologica in fase commerciale, con spazio per l'espansione. Questo stabilimento migliora la capacità di BeiGene di produrre farmaci innovativi contro il cancro su grande scala, ridurre i costi e garantire la resilienza della catena di approvvigionamento.
L'azienda prevede di creare centinaia di posti di lavoro altamente specializzati entro la fine del 2025. Il sito include misure di sostenibilità, come un sistema di riscaldamento e raffreddamento che utilizza acqua reflua trattata ed è predisposto per energia solare. Questa espansione supporta la strategia di crescita globale di BeiGene e rafforza la sua posizione come innovatore leader nell'oncologia con oltre 30 molecole in fase clinica o commerciale.
BeiGene (NASDAQ: BGNE) ha inaugurado su instalación principal en EE. UU. en Hopewell, N.J., lo que representa una inversión de 800 millones de dólares en la fabricación de biológicos y en capacidades de investigación y desarrollo clínico. El sitio de 42 acres cuenta con 400.000 pies cuadrados de capacidad de fabricación farmacéutica biológica en fase comercial, con espacio para expansión. Esta instalación mejora la capacidad de BeiGene para producir medicamentos innovadores contra el cáncer a gran escala, reducir costos y garantizar la resiliencia de la cadena de suministro.
La empresa planea crear cientos de empleos altamente especializados para finales de 2025. El sitio incluye medidas de sostenibilidad, como un sistema de calefacción y refrigeración que utiliza aguas residuales recicladas y está preparado para energía solar. Esta expansión apoya la estrategia de crecimiento global de BeiGene y refuerza su posición como líder innovador en oncología con más de 30 moléculas en etapa clínica o comercial.
BeiGene (NASDAQ: BGNE)는 뉴저지주 호프웰에 미국의 주요 시설을 개설하여 8억 달러의 투자를 생물학적 제조와 임상 연구 개발 능력에 투입했습니다. 42에이커의 부지는 40만 평방피트의 상업화 단계 생물학적 제약 생산 능력을 갖추고 있으며, 확장을 위한 공간도 마련되어 있습니다. 이 시설은 BeiGene이 혁신적인 암 의약품을 대규모로 생산하고, 비용을 낮추며, 공급망의 회복력을 확보할 수 있는 능력을 향상시킵니다.
회사는 2025년 말까지 수백 개의 고급 기술 직업을 창출할 계획입니다. 이 부지는 재활용된 폐수로 작동하는 난방 및 냉각 시스템과 태양광 설비에 대한 준비가 포함된 지속 가능성 조치를 포함하고 있습니다. 이러한 확장은 BeiGene의 글로벌 성장 전략을 지원하고 30개 이상의 분자가 임상 또는 상업 단계에 있는 선도적인 종양학 혁신가로서의 입지를 강화합니다.
BeiGene (NASDAQ: BGNE) a ouvert son installation phare aux États-Unis à Hopewell, N.J., représentant un investissement de 800 millions de dollars dans la fabrication de biologiques et les capacités de recherche et développement clinique. Le site de 42 acres dispose de 400 000 pieds carrés de capacité de fabrication pharmaceutique biologique à un stade commercial, avec de la place pour l'expansion. Cette installation améliore la capacité de BeiGene à produire des médicaments innovants contre le cancer à grande échelle, à réduire les coûts et à garantir la résilience de la chaîne d'approvisionnement.
L'entreprise prévoit de créer des centaines d'emplois qualifiés en haute technologie d'ici la fin de 2025. Le site comprend des mesures de durabilité telles qu'un système de chauffage et de climatisation utilisant des eaux usées recyclées et est prêt pour l'énergie solaire. Cette expansion soutient la stratégie de croissance mondiale de BeiGene et renforce sa position en tant qu'innovateur de premier plan en oncologie avec plus de 30 molécules au stade clinique ou commercial.
BeiGene (NASDAQ: BGNE) hat sein Hauptgebäude in den USA in Hopewell, N.J. eröffnet, was eine Investition von 800 Millionen US-Dollar in die Herstellung von Biologika sowie in klinische Forschungs- und Entwicklungsfähigkeiten darstellt. Das 42 Hektar große Gelände bietet 400.000 Quadratfuß an kommerzieller biologischer Pharmaproduktionskapazität, mit Platz für Erweiterungen. Diese Einrichtung verbessert die Fähigkeit von BeiGene, innovative Krebsmedikamente im großen Maßstab zu produzieren, Kosten zu senken und die Resilienz der Lieferkette zu gewährleisten.
Das Unternehmen plant, bis Ende 2025 Hunderte von hochqualifizierten Technologiearbeitsplätzen zu schaffen. Das Gelände umfasst Nachhaltigkeitsmaßnahmen wie ein Heiz- und Kühlsystem, das wiederaufbereitetes Abwasser verwendet, und ist auf Sonnenenergie vorbereitet. Diese Expansion unterstützt die globale Wachstumsstrategie von BeiGene und stärkt seine Position als führender Innovator in der Onkologie mit mehr als 30 Molekülen in klinischer oder kommerzieller Phase.
- $800 million investment in new U.S. biologics manufacturing and R&D facility
- 400,000 square feet of commercial-stage biologic pharmaceutical manufacturing capacity
- Expansion of late-stage research and clinical development capabilities
- Creation of hundreds of skilled high-tech jobs by the end of 2025
- Enhanced ability to produce innovative cancer medicines at scale
- Potential for cost reduction and improved supply chain resiliency
- None.
Insights
BeiGene's $800 million investment in a new U.S. facility is a significant move that underlines the company's commitment to expanding its production capabilities and global footprint. This substantial financial commitment is likely to reassure investors about BeiGene's financial stability and long-term vision. The new facility in New Jersey, a hub for biopharmaceutical innovation, enhances BeiGene's manufacturing and R&D capabilities. This expansion is strategically important as it will help the company meet the growing demand for its oncology drugs. By creating hundreds of high-tech jobs, BeiGene is also likely to benefit from local governmental support and incentives, further strengthening its financial position. The investment could lead to a more resilient supply chain, potentially reducing operational costs and increasing profit margins over time.
From a healthcare perspective, BeiGene's new U.S. facility represents a critical advancement in the fight against cancer. The ability to scale up production of innovative cancer treatments means more patients will have access to potentially life-saving medications. The integration of cutting-edge technologies in this facility suggests a focus on high-quality manufacturing processes, which can lead to more effective treatments with fewer side effects. Additionally, the company's robust pipeline, which includes targeted degraders, ADCs and monoclonal antibodies, positions BeiGene at the forefront of oncology innovation. This facility will likely accelerate the clinical development of new therapies, bringing them to market faster and benefiting patients around the globe more quickly.
BeiGene's expansion into New Jersey, a state with a strong biopharmaceutical sector, strategically places the company in a location rich with talent and resources. This move is consistent with the company's long-term strategy to become a leader in oncology. The investment in a state-of-the-art facility not only enhances production capacity but also strengthens BeiGene's market position. The addition of this facility is likely to improve supply chain resilience and reduce dependency on external suppliers, which is important in maintaining consistent product availability. Moreover, BeiGene’s commitment to sustainability in its operations may attract socially responsible investors, thereby expanding its investor base. This strategic positioning will likely boost investor confidence and support the company's stock value.
BeiGene's flagship biologics manufacturing facility and clinical R&D center at the Princeton West Innovation Campus in
“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation hematology and solid tumor medicines and continue to emerge as a leading global oncology innovator.”
BeiGene’s
“I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” said Governor Phil Murphy. “The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs in the Garden State. We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment. This significant investment highlights New Jersey’s role as a global leader in pharmaceutical manufacturing, research and development. We are proud to support BeiGene’s mission to develop affordable and accessible treatments for cancer patients worldwide.”
The site features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity with space to expand over time, allowing flexibility as BeiGene’s pipeline continues to mature. The facility adds to BeiGene’s late-stage research and clinical development capabilities, which have enabled the Company’s fast rise to global oncology leadership. BeiGene has built one of the industry’s deepest and most compelling oncology pipelines, addressing 80 percent of the world’s cancers with innovative modalities such as targeted degraders and antibody drug conjugates (ADCs), in addition to monoclonal antibodies and traditional small molecules. The new facility builds on BeiGene’s existing capabilities, enabling the Company to produce at scale, thereby reducing costs, ensuring supply chain resiliency, avoiding global disruptions, protecting capacity and rapidly adapting to the latest innovative modalities.
“I am excited to welcome BeiGene to
BeiGene recognizes that human health and the health of the planet are intrinsically linked, and the Company is committed to reducing our environmental impact. For this reason, the Company has invested in sustainability measures both in the buildings and surrounding 42 acres, including a heating and cooling system that uses recycled wastewater from the onsite wastewater treatment plant for the cooling towers. The site also is solar-ready in line with our longer-term sustainability plan. More details on the facility, including multimedia assets, are available online at: https://www.beigene.com/hopewell.
About BeiGene
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723282527/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
To access BeiGene media resources, please visit our News & Media site.
Source: BeiGene, Ltd.
FAQ
What is the size of BeiGene's investment in the new Hopewell, N.J. facility?
How many square feet of manufacturing capacity does the new BeiGene facility have?
How many jobs will BeiGene create at the new Hopewell facility by 2025?
What sustainability features are included in BeiGene's new Hopewell facility?
How many molecules does BeiGene (BGNE) have at clinical or commercial stage?
